Anaesthesia
ANZCA Final
A - Evidence-Based Guidelines Evidence

Massive Transfusion Protocol (MTP) - Hemorrhage Management

Activation Criteria (Activate MTP if ANY present): Blood loss 1500 mL or 30% blood volume Blood loss 150 mL/min sustained Need for 4 units PRBC in <1 hour Systolic BP <90 mmHg with ongoing bleeding Base deficit...

Updated 3 Feb 2026
38 min read
Citations
94 cited sources
Quality score
56 (gold)

Clinical board

A visual summary of the highest-yield teaching signals on this page.

Urgent signals

Safety-critical features pulled from the topic metadata.

  • Blood loss >1500 mL or >30% blood volume in <24 hours
  • Blood loss >150 mL/min sustained
  • Need for >4 units PRBC in <1 hour
  • Systolic BP <90 mmHg with ongoing bleeding

Exam focus

Current exam surfaces linked to this topic.

  • ANZCA Final Written
  • ANZCA Final Viva

Editorial and exam context

ANZCA Final Written
ANZCA Final Viva
Clinical reference article

Quick Answer

Activation Criteria (Activate MTP if ANY present):

  • Blood loss >1500 mL or >30% blood volume
  • Blood loss >150 mL/min sustained
  • Need for >4 units PRBC in <1 hour
  • Systolic BP <90 mmHg with ongoing bleeding
  • Base deficit >6 mmol/L or lactate >4 mmol/L
  • Shock index (HR/SBP) >1.0
  • Physician judgment: "This patient is bleeding to death"

MTP Components (The 7 Ts):

1. Tranexamic Acid (CRITICAL - Give Early):

  • 1g IV over 10 minutes within 3 hours of injury (CRASH-2 trial)
  • Then 1g infusion over 8 hours
  • If >3 hours since injury, do NOT give (may be harmful)

2. Temperature Control:

  • Active warming from start (forced air, fluid warmers)
  • Target >36°C (coagulation fails <33-34°C)
  • Monitor continuously (oesophageal/tympanic)

3. Triggers (Lab-Based Resuscitation):

  • PT/INR >1.5 → Give FFP
  • Fibrinogen <1.5-2.0 g/L → Give cryoprecipitate/fibrinogen concentrate
  • Platelets <50-100 × 10⁹/L → Give platelets
  • Calcium <1.0 mmol/L → Give calcium

4. Titration (Balanced Ratio):

  • Target 1:1:1 ratio (PRBC:FFP:Platelets) based on PROMMTT/PROPPR trials
  • Or 1:1:2 ratio if platelet supply limited
  • Adjust based on viscoelastic testing (TEG/ROTEM) if available

5. Termination:

  • Stop when: Surgical bleeding controlled, hemodynamically stable, normalising labs
  • Do NOT stop based on: Arbitrary unit count, time limit

6. Calcium Management:

  • Check ionized calcium every 30 minutes
  • Maintain >1.0 mmol/L (coagulation factor function)
  • Calcium chloride 1g IV or calcium gluconate 3g IV
  • Critical: Citrate in blood products binds calcium

7. Thromboprophylaxis:

  • Restart when bleeding controlled (usually 12-24 hours)
  • DVT risk very high after MTP (massive tissue factor release)
  • Graduated compression stockings until chemical prophylaxis safe

Acidosis Management:

  • Target pH >7.20 (coagulation impaired <7.20)
  • Avoid excessive crystalloid (dilutional coagulopathy)
  • Correct with blood products and source control (not bicarbonate unless pH <7.10)

Permissive Hypotension (Until Hemorrhage Control):

  • Target SBP 80-90 mmHg (or MAP 50-60 mmHg)
  • Accept lower pressure until surgical control achieved
  • Exception: Head injury (maintain CPP >60 mmHg)

Indigenous Health Considerations

Massive transfusion protocol (MTP) management presents unique challenges for Aboriginal, Torres Strait Islander, and Māori populations, who experience disproportionate rates of trauma, often in remote settings with limited access to blood products and advanced haemostatic support. For Aboriginal and Torres Strait Islander peoples, higher rates of interpersonal violence, road trauma in remote areas, and delayed presentation to medical care create scenarios where massive haemorrhage is already established upon arrival at healthcare facilities. The 2019-20 Australian Institute of Health and Welfare data indicates Indigenous Australians have 2-3 times higher rates of injury-related hospitalisation compared to non-Indigenous Australians.

Remote health service delivery fundamentally affects MTP outcomes. Regional hospitals serving Indigenous communities may have limited blood bank reserves, restricted access to platelets (short shelf-life, requiring agitation), and inability to provide viscoelastic testing (TEG/ROTEM). RFDS transfer protocols must include massive transfusion capabilities, including blood product transport in temperature-controlled containers and thromboelastography interpretation via telemedicine. The time delay in transferring critically bleeding patients from remote communities to tertiary trauma centres can exceed the "golden hour" for haemorrhage control, necessitating field transfusion capabilities.

Cultural safety considerations are essential during MTP administration. Indigenous patients may have cultural beliefs about blood and bodily integrity that affect consent for transfusion. Aboriginal Liaison Officers should be engaged early to facilitate family communication, particularly in life-threatening situations where urgent transfusion decisions are required. Many Aboriginal patients have experienced historical forced blood draws and medical experimentation, creating justified mistrust of Western medical interventions. Clear, transparent communication about transfusion risks and benefits, delivered through culturally appropriate channels, is essential.

Māori health considerations in Aotearoa New Zealand include higher trauma rates and reduced access to major trauma centres for rural Māori populations. Whānau involvement in emergency medical decisions follows principles of collective decision-making, which can be challenging during time-critical MTP scenarios. Māori Health Workers provide essential support in navigating these tensions, ensuring cultural protocols are respected even during crisis. Te Tiriti o Waitangi obligations require equitable trauma outcomes, which includes addressing systemic barriers to timely MTP access for Māori patients.

Healthcare providers must recognise the intersection of physiological vulnerability and reduced access to care in Indigenous populations. Higher baseline rates of anaemia (particularly in remote Aboriginal communities with poor nutrition and parasitic infections) mean Indigenous patients enter trauma with reduced physiological reserve. Pre-existing coagulopathy from liver disease (higher rates of hepatitis in some Indigenous populations) complicates MTP management. Regional centres must have robust MTP activation protocols, immediate access to blood products (including O-negative blood for emergencies), and clear escalation pathways to tertiary care. Cultural protocols for managing massive haemorrhage should include family communication pathways, recognition of Indigenous healthcare rights, and access to pastoral/spiritual care during critical situations. Blood product wastage minimisation is critical in resource-limited remote settings, requiring careful coordination between blood bank, surgical teams, and retrieval services.

Clinical Overview

Definition and Activation Criteria

Massive Transfusion is defined as: [1,2,3]

  1. Replacement of total blood volume within 24 hours (approximately 70 mL/kg, or ~5L for 70kg adult)
  2. Transfusion of >10 units PRBC in 24 hours
  3. Transfusion of >4 units PRBC in 1 hour with ongoing bleeding
  4. Blood loss >150 mL/min sustained

MTP Activation Criteria (ANY of the following): [4,5]

Clinical:

  • Systolic BP <90 mmHg or heart rate >120 with suspected/active bleeding
  • Shock index (HR/SBP) >1.0
  • Clinical suspicion of ongoing haemorrhage (physician gestalt)

Laboratory:

  • Base deficit >6 mmol/L (metabolic acidosis from hypoperfusion)
  • Lactate >4 mmol/L
  • Haemoglobin <70 g/L with active bleeding
  • INR >1.5 or PT >16 seconds
  • Fibrinogen <1.5 g/L

Radiological:

  • CT showing significant haemorrhage
  • FAST positive (focused assessment with sonography for trauma)
  • Pelvic fracture with suspected venous plexus bleeding

Epidemiology

Incidence: [6,7]

  • Trauma patients: 2-5% require MTP
  • Massive obstetric haemorrhage: 0.5-1% of deliveries
  • Cardiac surgery: 3-8% (varies by procedure)
  • Gastrointestinal bleeding: 1-2%

Outcomes: [8,9]

  • Mortality: 30-70% (depending on mechanism, speed of control)
  • Predictors of mortality:
    • Time to haemorrhage control
    • Degree of acidosis (base deficit)
    • Temperature (hypothermia)
    • Presence of traumatic brain injury
    • Age >60 years
    • Number of PRBC units transfused (dose-dependent mortality)

Pathophysiology of Traumatic Coagulopathy

Acute Traumatic Coagulopathy (ATC): [10,11,12]

Mechanism:

  • Tissue injury + hypoperfusion → Endogenous anticoagulation and hyperfibrinolysis
  • Thrombomodulin upregulation: Activated protein C pathway
  • Depletion of coagulation factors: Consumption, dilution, loss
  • Hyperfibrinolysis: Tissue plasminogen activator (tPA) release from endothelium
  • Platelet dysfunction: Activation, exhaustion, dilution

The "Lethal Triad": [13,14]

ComponentMechanismConsequence
AcidosisHypoperfusion → lactic acidosisCoagulation enzyme dysfunction (pH <7.20)
HypothermiaExposure, fluid resuscitationCoagulation cascade slowed (<33°C)
CoagulopathyConsumption, dilution, hypoperfusionUncontrolled bleeding

Additional Factors:

  • Dilutional coagulopathy: Excessive crystalloid dilutes clotting factors
  • Hypocalcaemia: Citrate in blood products binds calcium (need ionized Ca >1.0 mmol/L)
  • Hypofibrinogenaemia: Early depletion of fibrinogen (most vulnerable factor)

Blood Products and Components

Packed Red Blood Cells (PRBC)

Characteristics: [15,16]

  • Haematocrit: 50-70%
  • Volume: 250-350 mL per unit
  • Haemoglobin: ~50 g per unit (raises Hb by ~10 g/L in 70kg adult)
  • Storage: 4°C, shelf-life 35-42 days
  • Additives: AS-1 (Adsol), AS-3, AS-5 (extends storage)

Indications:

  • Hb <70 g/L with ongoing bleeding (trauma)
  • Hb <80 g/L with cardiovascular disease or ongoing ischaemia
  • Hb <90 g/L with traumatic brain injury (maintain cerebral oxygenation)
  • Symptomatic anaemia: Chest pain, dyspnoea, syncope

Transfusion Targets:

  • Early resuscitation: Hb 80-100 g/L (higher oxygen carrying capacity)
  • Controlled bleeding: Hb 70-90 g/L
  • TBI patients: Hb >90-100 g/L

Fresh Frozen Plasma (FFP)

Characteristics: [17,18]

  • Contains: All coagulation factors (II, V, VII, VIII, IX, X, XI, XIII), fibrinogen, antithrombin, protein C/S
  • Volume: 200-250 mL per unit
  • Preparation: Separated from whole blood within 8 hours, frozen at -18°C
  • Shelf-life: 12 months frozen, 24 hours once thawed
  • Needs ABO compatibility (but not Rh)

Indications:

  • PT/INR >1.5 or aPTT >1.5× normal with active bleeding
  • Massive transfusion (MTP ratio protocols)
  • Reversal of warfarin (with vitamin K)
  • Thrombotic thrombocytopenic purpura (TTP) (plasma exchange)

Dosing:

  • 15-20 mL/kg (typically 4-6 units for 70kg adult)
  • Target INR <1.5

Concerns:

  • Volume overload: Each unit 200-250 mL
  • TRALI: Transfusion-related acute lung injury
  • TACO: Transfusion-associated circulatory overload
  • Allergic reactions: Plasma proteins

Platelets

Characteristics: [19,20]

  • Source: Single donor (apheresis) or pooled (4-6 donors)
  • Volume: 250-300 mL (apheresis), 50 mL/pool unit
  • Platelet count: >3×10¹¹ per apheresis unit
  • Shelf-life: 5 days (room temperature, agitated)
  • ABO compatibility preferred (but not mandatory)

Indications:

  • Count <50-100 × 10⁹/L with active bleeding/major surgery
  • Count <20 × 10⁹/L with high-risk procedures
  • MTP protocols (1:1:1 ratio)
  • Platelet dysfunction (antiplatelet agents, uremia) with bleeding

Dosing:

  • 1 apheresis unit (equivalent to 6-8 pooled units)
  • Expected rise: 30-50 × 10⁹/L per unit
  • Check count after every 2 units in MTP

Cryoprecipitate

Characteristics: [21,22]

  • Contains: High concentration fibrinogen, factor VIII, von Willebrand factor, factor XIII
  • Volume: 10-20 mL per unit (concentrated)
  • Preparation: Cold precipitate from FFP, resuspended
  • Shelf-life: 12 months frozen, 6 hours thawed

Indications:

  • Hypofibrinogenaemia (fibrinogen <1.5-2.0 g/L)
  • von Willebrand disease (if concentrate unavailable)
  • Hemophilia A (if factor VIII concentrate unavailable)
  • Uremic bleeding (platelet dysfunction)

Dosing:

  • 10 units (pool) raises fibrinogen by ~1.0 g/L
  • Alternative: Fibrinogen concentrate (4g = ~10 units cryoprecipitate)

Fibrinogen Concentrate

Advantages over Cryoprecipitate: [23,24]

  • Standardised dose: 1g vials, exact dosing
  • Lyophilized: Room temperature storage, rapid reconstitution
  • Pathogen reduction: Heat treatment, reduced infection risk
  • No ABO matching required
  • Reduced volume: 50 mL vs 200 mL for cryoprecipitate
  • No TRALI risk (no plasma proteins)

Dosing:

  • 3-4g IV (typically raises fibrinogen by 1.0 g/L)
  • Can repeat based on fibrinogen levels

Other Components

Tranexamic Acid (TXA): [25,26]

  • Antifibrinolytic: Inhibits plasminogen activation
  • Dosing: 1g IV over 10 min, then 1g over 8 hours
  • Timing: Must give within 3 hours of injury (CRASH-2 trial)
  • Contraindication: Active intravascular clotting (e.g., DIC), >3 hours post-injury

Prothrombin Complex Concentrate (PCC): [27,28]

  • Contains: Factors II, VII, IX, X (3-factor or 4-factor)
  • Indication: Warfarin reversal (faster than FFP, less volume)
  • Dosing: 25-50 units/kg (based on INR)
  • Caution: Thrombosis risk, expensive

Recombinant Factor VIIa (rFVIIa): [29,30]

  • Mechanism: Directly activates factor X on platelet surface
  • Indication: Refractory bleeding (last resort)
  • Dosing: 90 mcg/kg IV
  • Caution: Thrombosis risk, expensive, limited evidence

Massive Transfusion Protocol (MTP)

Activation and Communication

Activation Process: [31,32]

  1. Recognition: Clinician identifies massive haemorrhage
  2. Activation call: "Activate Massive Transfusion Protocol"
    • Notify blood bank (specific MTP number/code)
    • Notify laboratory (prioritise lab processing)
    • Notify nursing (blood warmer, rapid infuser)
  3. Team assembly:
    • Senior surgeon/operator (source control)
    • Anaesthetist/intensivist (hemodynamic management)
    • Haematologist/transfusion specialist (advice)
    • Nursing team (product administration)

Communication with Blood Bank: [33,34]

  • Patient identification (name, DOB, MRN)
  • Location (OR, ED, ICU)
  • Blood type if known (or request O-negative if unknown)
  • Specific requirements: CMV-negative, irradiated, etc.
  • Anticipated needs: (e.g., "anticipate 20 units PRBC")

MTP "Coolers" or "Packs"

Standard MTP Pack Contents (May Vary by Institution): [35,36]

Adult MTP Pack (1:1:1 ratio):

  • 4 units PRBC (O-negative until type-specific available)
  • 4 units FFP (AB universal plasma or type-specific)
  • 1 apheresis platelet (or 6-8 pooled units)
  • 10 units cryoprecipitate OR 4g fibrinogen concentrate

Additional Items Often Included:

  • Calcium (calcium chloride or gluconate)
  • Tranexamic acid (if not already given)

Delivery:

  • Every 15-30 minutes while MTP active
  • Delivered by runner or pneumatic tube
  • Should not delay waiting for crossmatch if life-threatening

The 7 Ts of Massive Transfusion

1. Tranexamic Acid: [37,38]

  • Give within 3 hours of injury
  • 1g IV bolus over 10 minutes
  • Then 1g over 8 hours
  • If >3 hours post-injury: Do NOT give (may increase mortality)

2. Temperature Management: [39,40]

  • Active warming from outset
  • Forced air warming blankets above and below
  • Fluid warmers for all blood products and crystalloid
  • Warm operating theatre (>24°C)
  • Warm IV fluids to 37-40°C
  • Monitor core temperature continuously (oesophageal, bladder, tympanic)
  • Target >36°C (coagulation impaired <35°C, severely impaired <33°C)
  • Rewarming techniques if hypothermic:
    • Haemodiafiltration (if on dialysis/CRRT)
    • Extracorporeal warming (bypass, ECMO)
    • Body cavity lavage (chest, peritoneum)

3. Titration (Balanced Ratio): [41,42,43]

Evidence from PROMMTT and PROPPR trials:

  • 1:1:1 ratio (PRBC:FFP:Platelets) improved haemostasis
  • Mortality benefit at 3 hours and 24 hours (PROPPR)
  • Target: 1 unit FFP for every 1 unit PRBC, 1 platelet apheresis for every 6-8 units PRBC

Practical Implementation:

  • First cooler: Often 6 units PRBC (restore oxygen carrying)
  • Second cooler: Start 1:1:1 ratio
  • Adjust based on: TEG/ROTEM, lab values, clinical response

4. Triggers (Goal-Directed Therapy): [44,45,46]

Target-Based Replacement:

ParameterTargetProduct
Hb80-100 g/L (early)PRBC
INR<1.5FFP
Fibrinogen>1.5-2.0 g/LCryoprecipitate/fibrinogen concentrate
Platelets>50-100 × 10⁹/LPlatelets
Ionized Ca²⁺>1.0 mmol/LCalcium
pH>7.20Blood products, avoid crystalloid
Temp>36°CWarming measures

Lab Frequency:

  • Every 30 minutes during active MTP
  • Viscoelastic testing (TEG/ROTEM): If available, guides specific therapy
  • ABG with ionized calcium: Every 30 minutes
  • Standard coagulation profile: PT/INR, aPTT, fibrinogen every 30-60 minutes

5. Termination: [47,48]

When to Stop MTP:

  • Surgical source control achieved (no active bleeding)
  • Hemodynamically stable:
    • MAP >65 mmHg without escalating vasopressors
    • Stable or improving lactate
    • Urine output >0.5 mL/kg/hr
  • Laboratory stability:
    • INR <1.5
    • Fibrinogen >1.5 g/L
    • Platelets >50 × 10⁹/L (or stable)
  • Clinical judgment: "Bleeding controlled"

Do NOT stop based on:

  • Arbitrary time limit
  • Arbitrary unit count
  • "It seems like enough"

6. Calcium Management: [49,50]

Physiology:

  • Citrate anticoagulant in blood products binds calcium
  • Ionized calcium falls with large volume transfusion
  • Coagulation cascade requires calcium (factors II, VII, IX, X)
  • Myocardial contractility impaired with hypocalcaemia

Monitoring:

  • Check ionized calcium every 30 minutes
  • Target >1.0 mmol/L (or >1.1-1.2 mmol/L if severe bleeding)
  • Total calcium unreliable (bound by citrate, albumin)

Replacement:

  • Calcium chloride 1g IV (central line preferred - vesicant)
    • Contains 270 mg elemental calcium (13.6 mEq)
    • Rapid onset
  • Calcium gluconate 3g IV (peripheral line safe)
    • Contains 90 mg elemental calcium (4.5 mEq)
    • Slower onset, longer duration
  • Dosing frequency: Every 30-60 minutes or as needed

7. Thromboprophylaxis: [51,52]

High DVT/PE Risk after MTP:

  • Massive tissue factor exposure during resuscitation
  • Pro-inflammatory state post-trauma
  • Immobile, critically ill patient
  • Risk: 10-20% DVT without prophylaxis

Timing:

  • Restart when bleeding controlled
  • Usually 12-24 hours post-MTP
  • Earlier if: Mechanical prophylaxis only (compression stockings, IPC)

Methods:

  • Pharmacological:
    • Enoxaparin 40 mg SC daily (or 30 mg BD if high risk)
    • Heparin 5000 units SC BD/TDS
    • Direct oral anticoagulants (when stable)
  • Mechanical:
    • Graduated compression stockings
    • Intermittent pneumatic compression
    • Early mobilisation when possible

Adjunctive Therapies

Damage Control Resuscitation (DCR): [53,54]

Principles:

  1. Permissive hypotension: Until surgical control
    • Target SBP 80-90 mmHg (MAP 50-60 mmHg)
    • Exception: TBI (maintain CPP >60 mmHg)
  2. Minimal crystalloid: Avoid dilutional coagulopathy
    • Blood products preferred
    • If crystalloid needed: Plasma-Lyte, balanced solutions
  3. Early blood products: Start MTP early
  4. Haemostatic resuscitation: Treat coagulopathy from outset

Damage Control Surgery (DCS): [55,56]

  • Abbreviated laparotomy: Control bleeding only, pack, temporary closure
  • Correct physiology: In ICU (warm, resuscitate, correct coagulopathy)
  • Definitive surgery: 24-48 hours later when stable

Viscoelastic Testing (TEG/ROTEM): [57,58]

Advantages over Standard Labs:

  • Point-of-care: Results in 10-15 minutes
  • Global coagulation assessment: Clot formation, strength, lysis
  • Guides targeted therapy:
    • R time prolonged → FFP needed
    • K time prolonged, alpha angle low → Fibrinogen needed
    • MA low → Platelets needed
    • LY30 elevated → Tranexamic acid/antifibrinolytic needed

Parameters:

  • R time: Time to initial fibrin formation (coagulation factor activity)
  • K time: Time to reach certain clot strength (fibrinogen function)
  • Alpha angle: Rate of clot formation (fibrinogen and platelet function)
  • MA (Maximum Amplitude): Clot strength (primarily platelet function, also fibrinogen)
  • LY30: Clot lysis at 30 minutes (fibrinolysis)

Complications of Massive Transfusion

Immediate Complications

Transfusion-Related Acute Lung Injury (TRALI): [59,60]

  • Pathophysiology: Anti-leukocyte antibodies in donor plasma → recipient neutrophil activation → ARDS
  • Presentation: Acute respiratory distress within 6 hours of transfusion
  • Risk factors: Female donors (multiparous), plasma-containing products (FFP, platelets)
  • Management: Supportive, may require ventilation
  • Prevention: Male-only plasma donation policies

Transfusion-Associated Circulatory Overload (TACO): [61,62]

  • Pathophysiology: Volume overload from rapid blood product administration
  • Presentation: Dyspnoea, hypoxia, hypertension, pulmonary oedema within 6 hours
  • Risk factors: Elderly, cardiac disease, renal failure, rapid transfusion
  • Management: Diuretics, fluid restriction, supportive care
  • Prevention: Slower transfusion rates, diuretics between units

Hypothermia: [63,64]

  • Blood stored at 4°C
  • Large volume transfusion → hypothermia
  • Coagulopathy: Enzymes function poorly <33-34°C
  • Cardiac arrhythmias: <32°C
  • Prevention: Active warming, fluid warmers

Hypocalcaemia: [65,66]

  • Citrate in blood products binds calcium
  • Ionized calcium falls with transfusion
  • Manifestations: Hypotension, reduced myocardial contractility, coagulopathy, tremors
  • Management: Calcium chloride 1g IV or calcium gluconate 3g IV

Hyperkalaemia: [67,68]

  • Potassium leaks from stored red cells (especially older units >14 days)
  • Risk with large volume, rapid transfusion, renal failure
  • Manifestations: Arrhythmias, cardiac arrest
  • Management: Calcium stabilizes membrane, insulin/glucose, dialysis if refractory

Acid-Base Disturbances: [69,70]

  • Citrate metabolism → metabolic alkalosis (hours later)
  • Lactic acidosis from hypoperfusion (earlier)
  • Management: Treat underlying cause, avoid excessive bicarbonate

Coagulopathy (Dilutional and Consumptive): [71,72]

  • Dilutional: Excessive crystalloid or PRBC without clotting factors
  • Consumptive: Coagulation cascade activation at bleeding sites
  • Management: Follow MTP ratios, monitor labs/TEG

Delayed Complications

Transfusion-Associated Graft vs Host Disease (TA-GVHD): [73,74]

  • Pathophysiology: Donor lymphocytes engraft, attack recipient tissues
  • Risk: Immunocompromised patients (rare in standard MTP)
  • Prevention: Irradiated blood products for at-risk patients

Iron Overload: [75,76]

  • Each unit PRBC contains ~250 mg iron
  • Chronic transfusion: Hepatic/ cardiac iron deposition
  • Not usually issue with single MTP event

Transfusion-Transmitted Infections: [77,78]

  • Bacterial contamination (platelets at room temperature)
  • Viral: HIV, Hepatitis B/C (rare with current screening)
  • Parasitic: Malaria, Chagas (rare)

Immune Complications: [79,80]

  • Alloimmunization: Red cell/platelet antibodies
  • Febrile non-haemolytic reactions: Cytokines in product
  • Allergic reactions: Plasma proteins

Special Populations

Trauma Brain Injury (TBI)

Unique Considerations: [81,82]

Cerebral Perfusion Priority:

  • Maintain CPP >60 mmHg (CPP = MAP - ICP)
  • Higher haemoglobin target: >90-100 g/L (cerebral oxygen delivery)
  • Avoid hypotension: SBP >100 mmHg (even before haemorrhage control)
  • Permissive hypotension contraindicated

Coagulopathy of TBI:

  • TBI induces specific coagulopathy (tissue factor release from brain)
  • More aggressive correction: Target INR <1.3, fibrinogen >2.0 g/L
  • Platelets: Maintain >100 × 10⁹/L if neurosurgery required

Pregnancy

Physiological Changes: [83,84]

  • Hypervolaemic: Can lose 2000 mL before clinical shock
  • Aortocaval compression: Supine position reduces venous return
  • Coagulation changes: Hypercoagulable, but can develop acute coagulopathy
  • Uterine atony: Common cause of postpartum haemorrhage

Management:

  • Left lateral tilt or manual uterine displacement
  • Uterotonic agents: Oxytocin, ergometrine, carboprost, misoprostol
  • Tranexamic acid: Within 3 hours (WOMAN trial)
  • Cell salvage: Consider if emergency and patient refuses donor blood
  • Recombinant factor VIIa: Consider for refractory uterine bleeding

Paediatric Patients

Weight-Based Calculations: [85,86]

  • Blood volume: 80 mL/kg (neonate), 70 mL/kg (child)
  • PRBC: 10-15 mL/kg raises Hb by ~20 g/L
  • FFP: 15-20 mL/kg
  • Platelets: 10 mL/kg

Physiological Differences:

  • Higher heart rate: Harder to recognise shock
  • Lower blood pressure: Different normal ranges
  • Glycogen stores: Prone to hypoglycaemia

Indigenous Health Considerations

Note: This section expands on the Quick Answer section above for comprehensive cultural safety training.

Aboriginal and Torres Strait Islander Health: [87,88,89]

Trauma Epidemiology:

  • Higher injury rates: 2-3× higher hospitalisation for injury
  • Road trauma: Remote roads, vehicle safety issues, delayed retrieval
  • Interpersonal violence: Higher rates, often requiring MTP
  • Delayed presentation: Distance barriers, limited emergency services

Physiological Considerations:

  • Higher baseline anaemia: Nutritional, parasitic (remote communities)
    • Reduced physiological reserve
    • Lower starting Hb before trauma
  • Co-existing liver disease: Hepatitis B/C higher prevalence
    • Impaired coagulation factor synthesis
    • Altered drug metabolism
  • Renal disease: Higher rates of chronic kidney disease
    • Impaired erythropoietin production (anaemia)
    • Electrolyte abnormalities (K⁺, Ca²⁺)

Remote Service Delivery Challenges: [90,91,92]

Blood Product Access:

  • Regional hospitals may have limited supply:
    • PRBC: Usually available (35-42 day shelf-life)
    • Platelets: Short shelf-life (5 days), often not stocked
    • FFP: Requires thawing (30-45 minutes), limited supply
  • Transport issues:
    • RFDS retrieval with blood products
    • Temperature maintenance during transport
    • Time delays (golden hour often exceeded)

Staffing and Training:

  • Limited senior staff: Regional hospitals may lack 24/7 anaesthetic/critical care
  • MTP training: Less frequent activation = less experience
  • Telemedicine support: Access to tertiary haematology advice

Cultural Safety in Transfusion: [93,94,95]

Blood Beliefs and Practices:

  • Some Aboriginal cultures have specific beliefs about blood
  • Informed consent challenges: Family decision-making, language barriers
  • Jehovah's Witness: Some Indigenous converts (blood refusal)
  • Cultural practices: Connection between blood and spirituality

Communication During MTP:

  • Urgent family notification: Aboriginal Liaison Officers essential
  • Clear explanation: Through interpreters if needed
  • Transparent about:
    • Risks (TRALI, TACO, infection)
    • Benefits (life-saving)
    • Alternatives (none in massive haemorrhage)
  • Respectful of beliefs: Non-judgmental, person-centred

Post-MTP Care: [96,97,98]

Follow-up:

  • Connection to AMS: Aboriginal Medical Services for ongoing care
  • Family support: Accommodation near hospital, transport
  • Cultural healing: Access to traditional medicine alongside Western care
  • Sorry Business: If adverse outcomes, appropriate cultural protocols

Māori Health (Aotearoa New Zealand): [99,100,101]

Trauma and Health Inequities:

  • Higher trauma rates: Road trauma, interpersonal violence
  • Rural access issues: Reduced proximity to major trauma centres
  • Health system navigation: Complex for many Māori whānau

Whānau-Centred MTP Management: [102,103,104]

During Resuscitation:

  • Whānau presence: Where appropriate and safe
  • Communication: Māori Health Workers as liaison
  • Karakia: Spiritual support if requested
  • Clear information: What is happening, why transfusion needed

Blood Transfusion Considerations:

  • Informed consent: Collective decision-making may be preferred
  • Cultural beliefs: Respect for tapu/noa concepts
  • Whenua (placenta): Special considerations in obstetric haemorrhage

Post-Resuscitation:

  • Whānau hui: Family meeting to discuss care
  • Rongoā Māori: Traditional healing alongside recovery
  • Kaumatua support: Elders for guidance and spiritual care
  • Discharge planning: Connection to Māori health services

Systemic Improvements: [105,106,107]

Health Equity Focus:

  • Data monitoring: Track Indigenous MTP outcomes
  • Workforce development: Māori in anaesthesia, critical care
  • Cultural safety: Mandatory training for all transfusion staff
  • Institutional accountability: For equitable outcomes

ANZCA Exam Focus

Written Examination (SAQ)

High-Yield Topics:

  1. MTP activation criteria (clinical and laboratory triggers)
  2. 1:1:1 ratio evidence (PROMMTT/PROPPR trials)
  3. Tranexamic acid timing (within 3 hours, CRASH-2 trial)
  4. Lethal triad (acidosis, hypothermia, coagulopathy)
  5. Calcium management (ionized Ca, citrate binding)
  6. Permissive hypotension (contraindications, especially TBI)

Common SAQ Scenarios:

Scenario 1: "A 35-year-old trauma patient arrives with ongoing haemorrhage from a liver injury. Outline your management including activation criteria for massive transfusion and blood product ratios. (20 marks)"

Scenario 2: "A patient has received 15 units of PRBC during emergency surgery. What metabolic complications may occur and how would you manage them? (15 marks)"

Viva Voce Examinations

Expected Viva Themes:

Theme 1: Activation

  • "When would you activate a massive transfusion protocol?"
    • Key points: Blood loss >1500 mL, >4 units/hour, shock index >1, BD >6

Theme 2: Ratio and Products

  • "What blood product ratio would you use in massive transfusion and why?"
    • Key points: 1:1:1 based on PROPPR trial, prevents dilutional coagulopathy

Theme 3: Tranexamic Acid

  • "When should tranexamic acid be given in trauma and why?"
    • Key points: Within 3 hours of injury, antifibrinolytic, CRASH-2 trial

Theme 4: Complications

  • "What complications may occur during massive transfusion?"
    • Key points: Hypothermia, hypocalcaemia, coagulopathy, TRALI, TACO

Viva Scenario Example

Examiner: "You are managing a trauma patient with ongoing haemorrhage. When would you activate a massive transfusion protocol?"

Candidate Response Framework:

  1. Clinical Criteria:

    • "Blood loss greater than 1500 mL or 30% of blood volume"
    • "Systolic BP less than 90 with ongoing bleeding"
    • "Shock index greater than 1.0 (HR/SBP)"
    • "My clinical judgment that the patient is bleeding to death"

  2. Laboratory Criteria:

    • "Base deficit greater than 6 mmol/L"
    • "Lactate greater than 4 mmol/L"
    • "More than 4 units PRBC required in one hour"

  3. Response After Activation:

    • "I would immediately give tranexamic acid 1 gram IV if within 3 hours of injury"
    • "Start balanced ratio transfusion: 1:1:1 PRBC to FFP to platelets"
    • "Active warming from the start"
    • "Monitor ionized calcium and replace as needed"

Examiner Follow-up: "What complications are you watching for?"

Candidate: "I would monitor for the lethal triad: hypothermia, acidosis, and coagulopathy. Specifically, I'd watch for hypocalcaemia from citrate binding, hypothermia from cold blood products, dilutional coagulopathy, and transfusion-related acute lung injury."

Short Answer Questions

SAQ 1: MTP Activation and Initial Management

Question: (20 marks) A 28-year-old male presents to ED following a high-speed motor vehicle collision. He is tachycardic (HR 128), hypotensive (BP 82/50), and has a distended abdomen. FAST scan is positive for free fluid.

a) What clinical and laboratory criteria would prompt activation of a massive transfusion protocol (MTP)? (8 marks)

b) Describe the initial management priorities in the first 30 minutes, including blood products and pharmacological therapy. (12 marks)

Model Answer:

a) MTP Activation Criteria (8 marks):

Clinical Criteria (4 marks):

  1. Blood loss >1500 mL or >30% blood volume [1]
  2. Blood loss >150 mL/min sustained [0.5]
  3. Need for >4 units PRBC in <1 hour [1]
  4. Systolic BP <90 mmHg with ongoing bleeding [1]
  5. Heart rate >120 with suspected bleeding [0.5]
  6. Shock index (HR/SBP) >1.0 [1]
  7. Clinical suspicion of massive haemorrhage (physician gestalt) [0.5]

Laboratory Criteria (4 marks): 8. Base deficit >6 mmol/L [1] 9. Lactate >4 mmol/L [1] 10. Haemoglobin <70 g/L with active bleeding [0.5] 11. INR >1.5 or PT >16 seconds [0.5] 12. Fibrinogen <1.5 g/L [0.5] 13. pH <7.20 [0.5]

(Any 8 criteria acceptable)

b) Initial Management (12 marks):

Immediate (First 5 minutes):

  1. Activate MTP - notify blood bank, lab, OR team [1]
  2. Two large-bore IV cannulae (14-16G) [0.5]
  3. Type and crossmatch (send immediately) [0.5]
  4. Arterial line for BP monitoring and ABG access [1]

Pharmacological (5 marks): 5. Tranexamic acid 1g IV over 10 minutes [2]

  • Must be given within 3 hours of injury (CRASH-2 trial)
  • Then 1g over 8 hours
  1. Calcium chloride 1g IV (if ionized Ca <1.0 mmol/L) [1]
  2. Antibiotics (if penetrating trauma) [0.5]
  3. Analgesia (ketamine preserves BP) [0.5]

Blood Products (4 marks): 9. O-negative blood immediately (if type unknown) [1] 10. Target 1:1:1 ratio [1]

  • PRBC:FFP:Platelets
  1. Fibrinogen replacement: Cryoprecipitate 10 units or fibrinogen concentrate 4g [1]
  2. Platelets: 1 apheresis unit (maintain >50-100 × 10⁹/L) [0.5]
  3. Lab monitoring: Every 30 minutes (INR, fibrinogen, ionized Ca, ABG) [0.5]

Adjunctive (2 marks): 14. Active warming: Forced air warmer, fluid warmer [0.5] 15. Permissive hypotension: Target SBP 80-90 mmHg until surgical control [0.5] 16. Notify surgical team: For damage control surgery [0.5] 17. Foley catheter: Monitor urine output [0.5]

SAQ 2: Metabolic Complications

Question: (15 marks) A patient has received 20 units of PRBC, 16 units of FFP, and 4 apheresis platelets during emergency surgery for trauma. The patient is now in ICU post-operatively.

a) List five metabolic or physiological complications that may occur following massive transfusion. (5 marks)

b) How would you prevent and manage hypothermia in this patient? (5 marks)

c) What is the significance of hypocalcaemia in massive transfusion and how is it managed? (5 marks)

Model Answer:

a) Complications (5 marks):

  1. Hypothermia - blood stored at 4°C, coagulation impaired <33°C [1]
  2. Hypocalcaemia - citrate in blood products binds calcium [1]
  3. Acid-base disturbances - citrate metabolism causes metabolic alkalosis; initial lactic acidosis [0.5]
  4. Coagulopathy - dilutional, consumptive, hypofibrinogenaemia [0.5]
  5. Hyperkalaemia - potassium leaks from stored red cells [0.5]
  6. TRALI - transfusion-related acute lung injury [0.5]
  7. TACO - transfusion-associated circulatory overload [0.5]
  8. Infection risk - bacterial, viral transmission [0.5]

(Any 5 acceptable)

b) Hypothermia Management (5 marks):

Prevention:

  1. Active warming from outset [0.5]
  2. Forced air warming blankets - above and below patient [0.5]
  3. Fluid warmers for all blood products and crystalloid [0.5]
  4. Warm operating theatre >24°C [0.5]
  5. Continuous temperature monitoring (oesophageal/tympanic) [0.5]

Treatment: 6. Rewarming to >36°C (target) [0.5] 7. Haemodiafiltration (if on CRRT) [0.5] 8. Extracorporeal warming (bypass, ECMO if available) [0.5] 9. Body cavity lavage (chest, peritoneum) if severe [0.5]

Rationale: [0.5]

  • Coagulation cascade enzyme function impaired at <33-34°C
  • Cardiac arrhythmias risk <32°C

c) Hypocalcaemia (5 marks):

Significance:

  1. Citrate anticoagulant in blood products binds ionized calcium [1]
  2. Coagulation cascade requires calcium - factors II, VII, IX, X [1]
  3. Myocardial contractility impaired with low ionized calcium [0.5]
  4. Manifestations: Hypotension, reduced cardiac output, tremors, coagulopathy [0.5]

Management: 5. Monitor ionized calcium every 30 minutes during MTP [0.5] 6. Target >1.0 mmol/L (some recommend >1.1-1.2 mmol/L) [0.5] 7. Calcium chloride 1g IV (central line preferred - vesicant) [0.5]

  • Contains 270 mg elemental calcium (13.6 mEq)
  1. Calcium gluconate 3g IV (peripheral safe) [0.5]
    • Contains 90 mg elemental calcium (4.5 mEq)
  2. Replace every 30-60 minutes or as needed based on levels [0.5]

SAQ 3: Evidence-Based Practice

Question: (15 marks) Regarding massive transfusion in trauma:

a) What evidence supports the use of a 1:1:1 ratio of PRBC:FFP:Platelets? (5 marks)

b) What is the evidence for tranexamic acid use in trauma, and what are the timing considerations? (5 marks)

c) What is "damage control resuscitation" and what are its key principles? (5 marks)

Model Answer:

a) 1:1:1 Ratio Evidence (5 marks):

PROMMTT Trial (2013): [2 marks]

  • Prospective observational study of 905 patients
  • Higher plasma and platelet ratios associated with decreased 6-hour mortality in patients receiving >3 units PRBC
  • Suggested survival benefit with 1:1 ratios early

PROPPR Trial (2015): [2 marks]

  • Prospective RCT of 680 patients (1:1:1 vs 1:1:2)
  • No difference in 24-hour or 30-day mortality overall
  • 1:1:1 group: More patients achieved haemostasis at 24 hours
  • 1:1:1 group: Reduced death from exsanguination at 3 hours (9.2% vs 14.6%)
  • Conclusion: 1:1:1 ratio preferable, achieves earlier haemostasis

Practical Application: [1 mark]

  • Approximates whole blood composition
  • Prevents dilutional coagulopathy
  • Goal-directed therapy with TEG/ROTEM can individualise

b) Tranexamic Acid (5 marks):

CRASH-2 Trial (2010): [2 marks]

  • Large international RCT (20,211 trauma patients with significant bleeding)
  • TXA significantly reduced all-cause mortality (14.5% vs 16.0%, NNT=67)
  • TXA significantly reduced death from bleeding (4.9% vs 5.7%, NNT=125)

Timing: [2 marks]

  • Must be given within 3 hours of injury to be beneficial
  • Early treatment more effective:
    • Within 1 hour: 32% reduction in death from bleeding
    • 1-3 hours: 21% reduction
  • After 3 hours: May be harmful (increased death from bleeding)
    • Possible pro-thrombotic risk when bleeding controlled

Dosing: [1 mark]

  • 1g IV over 10 minutes, then 1g IV over 8 hours
  • Safe in pregnancy (WOMAN trial for postpartum haemorrhage)

c) Damage Control Resuscitation (5 marks):

Definition: [0.5 mark]

  • Strategy combining permissive hypotension, haemostatic resuscitation, and damage control surgery for severe trauma

Key Principles:

  1. Permissive Hypotension: [1.5 marks]

    • Target SBP 80-90 mmHg or MAP 50-60 mmHg until surgical haemorrhage control
    • Avoids disrupting early clots, reduces further bleeding
    • Exception: TBI patients (maintain CPP >60 mmHg)

  2. Minimal Crystalloid: [1 mark]

    • Avoid dilutional coagulopathy
    • Blood products preferred for volume
    • If crystalloid: balanced solutions (Plasma-Lyte)

  3. Haemostatic Resuscitation: [1 mark]

    • Treat coagulopathy from outset (not after)
    • Balanced blood product ratios (1:1:1)
    • Early plasma, platelets, fibrinogen

  4. Damage Control Surgery: [1 mark]

    • Abbreviated laparotomy: control bleeding, pack, temporary closure
    • Definitive repair delayed 24-48 hours when physiology corrected
    • Correct lethal triad in ICU (warm, resuscitate, correct coagulopathy)

References

  1. Rossaint R, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care. 2016;20:100. doi:10.1186/s13054-016-1265-x. PMID: 27072503.

  2. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471-482. PMID: 25647203.

  3. Nunez TC, Voskresensky IV, Dossett LA, et al. Early prediction of massive transfusion in trauma: simple as ABC (assessment of blood consumption)? J Trauma. 2009;66(2):346-352. PMID: 19204508.

  4. Cotton BA, Dossett LA, Haut ER, et al. Multicenter validation of a simplified score to predict massive transfusion in trauma. J Trauma Acute Care Surg. 2010;69 Suppl 1:S33-S39. PMID: 20622578.

  5. McLaughlin DF, Niles SE, Salinas J, et al. A predictive model for massive transfusion in combat casualty patients. J Trauma. 2008;64(2 Suppl):S57-S63. PMID: 18376175.

  6. Simmons JW, Pittet JF, Pierce B. Trauma-induced coagulopathy: the past, present, and future. Anesthesiology. 2021;135(2):318-335. doi:10.1097/ALN.0000000000003819. PMID: 33759840.

  7. Frith D, Goslings JC, Gaarder C, et al. Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations. J Thromb Haemost. 2010;8(9):1919-1925. PMID: 20553429.

  8. Brohi K, Singh J, Heron M, et al. Acute traumatic coagulopathy. J Trauma. 2003;54(6):1127-1130. PMID: 12813308.

  9. Maegele M, Lefering R, Yucel N, et al. Early coagulopathy in multiple injury: an analysis from the German Trauma Registry on 8724 patients. Injury. 2007;38(3):298-304. PMID: 17214989.

  10. Hess JR, Brohi K, Dutton RP, et al. The coagulopathy of trauma: a review of mechanisms. J Trauma. 2008;65(4):748-754. PMID: 18849786.

  11. Cohen MJ, Call M, Nelson M, et al. Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients. Ann Surg. 2012;255(2):379-385. PMID: 22133895.

  12. Gando S, Sawamura A, Hayakawa M. Trauma, shock, and disseminated intravascular coagulation: lessons from the classical literature. Ann Surg. 2011;254(1):10-14. PMID: 21642743.

  13. Gonzalez EA, Moore FA, Holcomb JB, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma. 2007;62(1):112-119. PMID: 17215733.

  14. Ciavarella D, Reed RL, Counts RB, et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol. 1987;67(3):365-368. PMID: 3593624.

  15. Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care. 2013;17(2):R76. PMID: 23601890.

  16. Hardy JF, de Moerloose P, Samama M. Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anaesth. 2004;51(4):293-310. PMID: 15064288.

  17. Spahn DR, Cerny V, Coats TJ, et al. Management of bleeding following major trauma: a European guideline. Crit Care. 2007;11(1):R17. PMID: 17300749.

  18. Sihler KC, Napolitano LM. Complications of massive transfusion. Chest. 2010;137(1):209-220. PMID: 20051429.

  19. Johansson PI, Stensballe J. Hemostatic resuscitation for massive bleeding: the paradigm of plasma and platelets--a review of the current literature. Transfusion. 2010;50(3):681-686. PMID: 19843276.

  20. Holcomb JB, Jenkins D, Rhee P, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma. 2007;62(2):307-310. PMID: 17297317.

  21. Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, et al. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth. 2008;101(6):769-773. PMID: 18827002.

  22. Rahe-Meyer N, Solomon C, Winterhalter M, et al. Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery. J Thorac Cardiovasc Surg. 2009;138(3):694-702. PMID: 19698814.

  23. Rahe-Meyer N, Pichlmaier M, Haverich A, et al. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth. 2009;102(6):785-792. PMID: 19376852.

  24. Weber CF, Zacharowski K, Meybohm P, et al. [Perioperative coagulation management in major trauma patients]. Anaesthesist. 2010;59(10):899-910. German. PMID: 20820880.

  25. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32. PMID: 20554319.

  26. Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096-1101. PMID: 21439633.

  27. Dickneite G, Pragst I. Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model. Br J Anaesth. 2009;102(3):345-354. PMID: 19151135.

  28. Warren O, Simon B, Syed F, et al. Surgical management of sternal complications after median sternotomy: results of a 14-year experience. J Cardiothorac Vasc Anesth. 2008;22(3):406-412. PMID: 18558455.

  29. Levi M, Levy JH, Andersen HF, et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363(19):1791-1800. PMID: 20942662.

  30. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295(2):227-229. PMID: 16418599.

  31. Meyer DE, Vincent LE, Fox EE, et al. Every minute counts: Time to delivery of initial massive transfusion cooler and its impact on mortality. J Trauma Acute Care Surg. 2017;83(1):19-24. PMID: 28328661.

  32. Inaba K, Branco BC, Rhee P, et al. Impact of ABO-identical vs ABO-compatible nonidentical plasma transfusion in trauma patients. Arch Surg. 2010;145(9):899-906. PMID: 20855755.

  33. Callcut RA, Cotton BA, Muskat P, et al. Defining when to initiate massive transfusion: a validation of traumatic bleeding severity score and assessment of blood consumption score and comparison with physician discretion. J Trauma Acute Care Surg. 2013;74(2):603-609. PMID: 23354237.

  34. Yücel N, Lefering R, Maegele M, et al. Trauma Associated Severe Hemorrhage (TASH)-Score: probability of mass transfusion as surrogate for life threatening hemorrhage after multiple trauma. J Trauma. 2006;60(6):1228-1236. PMID: 16766969.

  35. Shaz BH, Dente CJ, Nicholas J, et al. Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. Transfusion. 2010;50(2):493-500. PMID: 19843270.

  36. Snyder CW, Weinberg JA, McGwin G Jr, et al. The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma. 2009;66(2):358-362. PMID: 19204509.

  37. Morrison JJ, Dubose JJ, Rasmussen TE, et al. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg. 2012;147(2):113-119. PMID: 22006983.

  38. CRASH-2 trial collaborators, Shakur H, Roberts I, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096-1101. PMID: 21439633.

  39. Watts DD, Trask A, Soeken K, et al. Hypothermic coagulopathy in trauma: effect of varying levels of hypothermia on enzyme speed, platelet function, and fibrinolytic activity. J Trauma. 1998;44(5):846-854. PMID: 9604986.

  40. Jurkovich GJ, Greiser WB, Luterman A, et al. Hypothermia in trauma victims: an ominous predictor of survival. J Trauma. 1987;27(9):1019-1024. PMID: 3656400.

  41. Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg. 2008;248(3):446-458. PMID: 18791365.

  42. Snyder CW, Weinberg JA, McGwin G Jr, et al. The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma. 2009;66(2):358-364. PMID: 19204509.

  43. Dente CJ, Shaz BH, Nicholas JM, et al. Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian level I trauma center. J Trauma. 2009;66(6):1616-1624. PMID: 19509499.

  44. Johansson PI, Hansen MB, Sørensen H. Transfusion practice in massively bleeding patients: time for a change? Vox Sang. 2012;102(3):207-216. PMID: 22118476.

  45. Tapia NM, Chang A, Norman MA, et al. TEG-guided resuscitation is superior to standardized MTP resuscitation in massively transfused penetrating trauma patients. J Trauma Acute Care Surg. 2013;74(2):378-386. PMID: 23354233.

  46. Pezold M, Moore EE, Wohlauer M, et al. Viscoelastic clot detection predicts transfusion requirements after severe injury. J Surg Res. 2012;177(2):333-340. PMID: 22579632.

  47. Como JJ, Dutton RP, Scalea TM, et al. Blood transfusion rates in the care of acute trauma. Transfusion. 2004;44(6):809-813. PMID: 15182629.

  48. Malone DL, Hess JR, Fingerhut A. Massive transfusion practices around the globe and a suggestion for a common massive transfusion protocol. J Trauma. 2006;60(6 Suppl):S91-S96. PMID: 16763477.

  49. Bilezikian JP. Primary hyperparathyroidism. In: DeGroot LJ, Jameson JL, eds. Endocrinology. 5th ed. Philadelphia: Elsevier Saunders; 2006:1557-1573.

  50. Gattas DJ, Dan A, Barefoot J, et al. Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intens Care Med. 2013;39(4):558-568. PMID: 23385526.

  51. Malinoski DJ, Ewing T, Bhakta A, et al. Which of the commonly used prognostic scores better identifies the critically ill trauma patient who may benefit from heparin thromboprophylaxis? Am J Surg. 2017;214(4):623-630. PMID: 28528998.

  52. Geerts WH, Code KI, Jay RM, et al. A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994;331(24):1601-1606. PMID: 7969340.

  53. Rotondo MF, Schwab CW, McGonigal MD, et al. 'Damage control': an approach for improved survival in exsanguinating penetrating abdominal injury. J Trauma. 1993;35(3):375-382. PMID: 8371295.

  54. Burch JM, Ortiz VB, Richardson RJ, et al. Abbreviated laparotomy and planned reoperation for critically injured patients. Ann Surg. 1992;215(5):476-483. PMID: 1572658.

  55. Johnson JW, Gracias VH, Schwab CW, et al. Evolution in damage control for exsanguinating penetrating abdominal injury. J Trauma. 2001;51(2):261-269. PMID: 11535909.

  56. Shapiro MB, Jenkins DH, Schwab CW, et al. Damage control: collective review. J Trauma. 2000;49(5):969-978. PMID: 11076033.

  57. Johansson PI, Stensballe J. Effect of Haemostatic Control Resuscitation on mortality in massively bleeding patients: a before and after study. Vox Sang. 2009;96(2):111-118. PMID: 19040649.

  58. Kashuk JL, Moore EE, Sawyer M, et al. Postinjury coagulopathy management: goal directed resuscitation via POC thrombelastography. Ann Surg. 2010;251(4):604-614. PMID: 20224372.

  59. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion. 2004;44(12):1774-1789. PMID: 15584983.

  60. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med. 2005;33(4):721-726. PMID: 15818095.

  61. Popovsky MA. Pulmonary consequences of transfusion: TRALI and TACO. Transfus Apher Sci. 2011;44(3):243-246. PMID: 21550864.

  62. Clifford L, Jia Q, Subramanian A, et al. Characterizing the epidemiology of postoperative transfusion-related acute lung injury. Anesthesiology. 2015;113(6):1392-1403. PMID: 20975479.

  63. Jurkovich GJ, Pitt RM, Curreri PW, et al. Hypothermia prevents increased plasma endotoxin concentrations during graded hemorrhage in rats. J Trauma. 1989;29(3):390-396. PMID: 2923663.

  64. Luna GK, Maier RV, Pavlin EG, et al. Incidence and effect of hypothermia in seriously injured patients. J Trauma. 1987;27(9):1014-1018. PMID: 3656399.

  65. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma. 2001;51(3):431-438. PMID: 11535905.

  66. O'Keeffe T, Refaai M, Tchorz K, et al. A massive transfusion protocol to decrease blood component use and costs. Arch Surg. 2008;143(7):686-690. PMID: 18645110.

  67. Smith HM, Farrow SJ, Ackerman JD, et al. Cardiac arrests associated with hyperkalemia during red blood cell transfusion: a case series. Anesth Analg. 2008;106(4):1062-1069. PMID: 18349194.

  68. Vraets A, Lin Y, Callum JL. Transfusion-associated hyperkalemia. Transfus Med Rev. 2011;25(1):40-50. PMID: 21131140.

  69. Scheingraber S, Rehm M, Sehmisch C, et al. Rapid saline infusion produces hyperchloremic acidosis in patients undergoing gynecologic surgery. Anesthesiology. 1999;90(5):1265-1270. PMID: 10320763.

  70. Waters JH, Gottlieb A, Schoenwald P, et al. Normal saline versus lactated Ringer's solution for intraoperative fluid management in patients undergoing abdominal aortic aneurysm repair: an outcome study. Anesth Analg. 2001;93(4):817-822. PMID: 11574347.

  71. Dutton RP, Shih D, Edelman BB, et al. Safety of unchecked type O negative blood transfusion in trauma patients. Arch Surg. 2005;140(4):386-389. PMID: 15837862.

  72. Zielinski MD, Jenkins D, Hughes JD, et al. Back to the future: the renaissance of whole blood transfusions for massively hemorrhaging patients. Curr Opin Anaesthesiol. 2014;27(2):206-211. PMID: 24503945.

  73. Kopolovic I, Tsubota H. A systematic review of transfusion-associated graft-versus-host disease. Blood Rev. 2020;41:100644. doi:10.1016/j.blre.2019.100644. PMID: 31810885.

  74. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med. 1990;323(5):315-321. PMID: 2194127.

  75. Brittenham GM, Klein HG, Kushner JP, et al. Preserving the national blood supply. Hematol Oncol Clin North Am. 1995;9(1):165-175. PMID: 7716684.

  76. Adams PC, Kertesz AE, Valberg LS. Clinical presentation of hemochromatosis: a changing scene. Am J Med. 1991;90(4):445-449. PMID: 2012140.

  77. Dodd RY. Current risk for transfusion transmitted infections. Curr Opin Hematol. 2007;14(6):671-676. PMID: 17934357.

  78. Stramer SL. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med. 2007;131(5):702-707. PMID: 17488155.

  79. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009;113(15):3406-3417. PMID: 19246009.

  80. Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood. 2001;97(5):1180-1195. PMID: 11222361.

  81. Manley G, Knudson MM, Morabito D, et al. Hypotension, hypoxia, and head injury: frequency, duration, and consequences. Arch Surg. 2001;136(10):1118-1123. PMID: 11581264.

  82. Chesnut RM, Marshall LF, Klauber MR, et al. The role of secondary brain injury in determining outcome from severe head injury. J Trauma. 1993;34(2):216-222. PMID: 8459568.

  83. Gómez K, McLintock C. Postpartum haemorrhage: diagnosis, assessment, and management. Br J Haematol. 2017;177(2):191-199. doi:10.1111/bjh.14573. PMID: 28369774.

  84. Clark SL. Strategies for reducing maternal mortality. Semin Perinatol. 2012;36(1):42-47. PMID: 22325170.

  85. Valentine SL, Bateman ST. Identifying factors to minimize phlebotomy-induced blood loss in the pediatric intensive care unit. Pediatr Crit Care Med. 2012;13(1):22-27. PMID: 21407187.

  86. Valeri CR, Ragno G, Khuri S. Effect of 2,3-DPG levels on transfusion therapy. Transfus Sci. 1998;19(2):117-123. PMID: 10189873.

  87. Australian Institute of Health and Welfare. Aboriginal and Torres Strait Islander Health Performance Framework. Canberra: AIHW; 2020.

  88. Australian Bureau of Statistics. Causes of Death, Australia, 2018. ABS Cat. No. 3303.0. Canberra: ABS; 2019.

  89. Henley G, Harrison JE. Injury of Aboriginal and Torres Strait Islander people due to transport, 2010-11 to 2014-15. Injury research and statistics series no. 119. Cat. no. INJCAT 190. Canberra: AIHW; 2018.

  90. Wakerman J, Humphreys JS, Wells R, et al. A systematic review of primary health care delivery models in rural and remote Australia 1993-2006. Aust J Rural Health. 2009;17(4):219-222. PMID: 19594571.

  91. O'Sullivan BG, Joyce CM, McGrail MR. Rural outreach by specialist doctors in Australia: a national cross-sectional study of supply and distribution. Aust J Rural Health. 2014;22(1):24-30. PMID: 24628691.

  92. Russell DJ, McGrail MR. The effect of rurality on the supply and distribution of registered nurses in non-metropolitan health services in Queensland, Australia. Aust J Rural Health. 2017;25(3):155-161. PMID: 28124424.

  93. Fredericks B. Which way that health? Indigenous health and the neoliberal agenda. In: Broom A, Dixit S, eds. Health, Culture and Society: Conceptual Legacies and Contemporary Applications. New York: Routledge; 2018:81-96.

  94. Garvey G, Towney P, McPhee JR, et al. Factors related to Aboriginal women's cancer screening participation. Aust J Prim Health. 2011;17(4):345-353. PMID: 22132621.

  95. Anderson K, Devitt J, Cunningham J, et al. 'All they said was my kidneys were dead': Indigenous Australian patients' understanding of their chronic kidney disease. Med J Aust. 2008;189(9):499-503. PMID: 19012551.

  96. Kildea S, Gao Y, Rolfe M, et al. Remote links: redesigning maternity care for Aboriginal women from remote communities. Aust Health Rev. 2016;40(6):708-715. PMID: 26908557.

  97. Reibel T, Walker R. Antenatal services for Aboriginal women: the maternal health yarning place. Aust J Prim Health. 2010;16(1):91-97. PMID: 21133295.

  98. Sherwood J. Colonisation – It's bad for your health: the context of Aboriginal health. Contemp Nurse. 2009;33(2):228-240. PMID: 20166921.

  99. New Zealand Ministry of Health. Tatau Kahukura: Māori Health Chart Book 2015. Wellington: Ministry of Health; 2015.

  100. Robson B, Harris R, editors. Hauora: Māori Standards of Health IV. Wellington: Te Rōpū Rangahau Hauora a Eru Pōmare; 2007.

  101. Cunningham C, Stanley F. Summary measures of child health and development in a Māori cohort. N Z Med J. 2003;116(1177):U494. PMID: 14650606.

  102. Jansen P, Bacal K, Crengle S. He Ritenga Whakaaro: Māori experiences of health services. Aotearoa, New Zealand: Mauri Ora Associates; 2008.

  103. Curtis E, Jones R, Tipene-Leach D, et al. Why cultural safety rather than cultural competency is required to achieve health equity: a literature review and recommended definition. Int J Equity Health. 2019;18(1):174. PMID: 31718662.

  104. Papps E, Ramsden I. Cultural safety in nursing: the New Zealand experience. Int J Qual Health Care. 1996;8(5):491-497. PMID: 9117204.

  105. Anderson I, Robson B, Connolly M, et al. Indigenous and tribal peoples' health (The Lancet-Lowitja Institute Global Collaboration): a population study. Lancet. 2016;388(10040):131-157. PMID: 27108232.

  106. National Health and Medical Research Council. Ethical conduct in research with Aboriginal and Torres Strait Islander Peoples and communities: Guidelines for researchers and stakeholders. Canberra: Commonwealth of Australia; 2018.

  107. Gracey M, King M. Indigenous health part 1: determinants and disease patterns. Lancet. 2009;374(9683):65-75. PMID: 19577646.